Comparison of Two Corticosteroid Regimens for Post COVID-19 Diffuse Lung Disease
Status:
Recruiting
Trial end date:
2021-12-07
Target enrollment:
Participant gender:
Summary
A proportion of patients with COVID-19 pneumonia have a prolonged course of illness. Some of
these patients continue to have considerable respiratory symptoms or persistent hypoxemia.
The CT abnormalities in these patients are often a combination of ground-glass opacities and
patchy multifocal consolidation consistent with a pattern of OP. In several patients, these
radiologic abnormalities persist. As with other forms of OP, patients with post-COVID OP or
post COVID diffuse lung disease (PC-DLD) may benefit from treatment with oral
glucocorticoids. The ideal dose of glucocorticoids for treating PC-DLD is unknown.
In this study, the investigatros aim to compare the efficacy and safety of a medium dose and
a low dose of prednisolone (as the initial dose) for the treatment of post-COVID. diffuse
lung disease.
Phase:
N/A
Details
Lead Sponsor:
Postgraduate Institute of Medical Education and Research